Patents by Inventor Michal ZIMMERMANN

Michal ZIMMERMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION TREATMENT OF CANCERS
    Publication number: 20250090539
    Abstract: Provided herein are, inter alia, methods and compositions for the treatment of cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of Ataxia-telangiectasia and RAD-3-related protein (ATR) kinase inhibitors (e.g., camonsertib), pharmaceutically acceptable salts thereof, or pharmaceutical composition containing the same, and an antimetabolite (e.g., gemcitabine), pharmaceutically acceptable salts thereof, or pharmaceutical composition containing the same.
    Type: Application
    Filed: September 18, 2024
    Publication date: March 20, 2025
    Inventors: Michal Zimmermann, Anne Roulston, Julia Yang, Danielle Ulanet
  • USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS
    Publication number: 20240350505
    Abstract: Disclosed are methods of treating a cancer in a subject using an ATR inhibitor and PARP inhibitor. wherein the cancer has been previously identified as a cancer having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or as an ALT+ cancer. Also disclosed are methods of inducing cell death in an aberrant cancer cell having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or an ALT+ cancer cell, by contacting the cell with an effective amount of an ATR inhibitor and PARP inhibitor.
    Type: Application
    Filed: December 12, 2023
    Publication date: October 24, 2024
    Inventors: Michal Zimmermann, Anne Roulston, Maria Koehler
  • USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS FOR TREATING CANCER
    Publication number: 20240173330
    Abstract: Disclosed are methods of treating a cancer in a subject using an ATR inhibitor and PARP inhibitor. wherein the cancer has been previously identified as a cancer having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or as an ALT+ cancer. Also disclosed are methods of inducing cell death in an aberrant cancer cell having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or an ALT+ cancer cell, by contacting the cell with an effective amount of an ATR inhibitor and PARP inhibitor.
    Type: Application
    Filed: December 14, 2023
    Publication date: May 30, 2024
    Inventors: Cameron Black, Michal Zimmermann
  • USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS
    Publication number: 20210177856
    Abstract: Disclosed are methods of treating a cancer in a subject using an ATR inhibitor and PARP inhibitor. wherein the cancer has been previously identified as a cancer having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or as an ALT+ cancer. Also disclosed are methods of inducing cell death in an aberrant cancer cell having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or an ALT+ cancer cell, by contacting the cell with an effective amount of an ATR inhibitor and PARP inhibitor.
    Type: Application
    Filed: December 11, 2020
    Publication date: June 17, 2021
    Inventors: Michal ZIMMERMANN, Anne ROULSTON, Maria KOEHLER